Skip to content

CYTOSORBENTS CORPORATION: 10-K filed 2025-03-31

What CYTOSORBENTS CORPORATION reported in its annual report filed 2025-03-31 (fiscal FY 2024): 48 published measures, 169 facts as tagged in accession 0001410578-25-000591.

This filing

Form
10-K (annual report)
Filed
2025-03-31
Fiscal period
fiscal FY 2024
Accession
0001410578-25-000591 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYTOSORBENTS CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-12-3147,371,500USD
At 2024-09-3047,804,011USD
At 2024-06-3053,426,791USD
At 2024-03-3147,070,605USD
At 2023-12-3152,956,322USD
At 2023-09-3047,575,037USD
At 2023-06-3052,444,767USD
At 2023-03-3157,462,835USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-12-3136,264,564USD
At 2024-09-3034,659,139USD
At 2024-06-3035,998,168USD
At 2024-03-3127,442,223USD
At 2023-12-3129,475,108USD
At 2023-09-3028,763,450USD
At 2023-06-3027,984,195USD
At 2023-03-3127,524,898USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-12-3111,106,936USD
At 2024-09-3013,144,872USD
At 2024-06-3017,428,622USD
At 2024-03-3119,628,382USD
At 2023-12-3123,481,214USD
At 2023-09-3018,811,587USD
At 2023-06-3024,460,572USD
At 2023-03-3129,937,937USD
At 2022-12-3135,374,973USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-12-313,279,926USD
At 2023-12-3114,131,137USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-20,718,957USD366
2023-01-01 to 2023-12-31-29,246,760USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-14,427,809USD366
2023-01-01 to 2023-12-31-21,655,136USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-12-31284,343USD366
2023-01-01 to 2023-12-31538,115USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-12-319,330,704USD366
2023-01-01 to 2023-12-3114,474,210USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-669,430USD366
2023-01-01 to 2023-12-31-936,236USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-12-31-304,008,618USD
At 2024-09-30-296,439,703USD
At 2024-06-30-293,673,480USD
At 2024-03-31-289,378,372USD
At 2023-12-31-283,289,661USD
At 2023-09-30-277,135,226USD
At 2023-06-30-267,965,940USD
At 2023-03-31-261,364,727USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-12-3154,434,609shares366
2023-01-01 to 2023-12-3144,656,391shares365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-12-3154,434,609shares366
2023-01-01 to 2023-12-3144,656,391shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-0.38USD/shares366
2024-07-01 to 2024-09-30-0.05USD/shares92
2024-01-01 to 2024-09-30-0.24USD/shares274
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-06-30-0.19USD/shares182
2024-01-01 to 2024-03-31-0.11USD/shares91
2023-01-01 to 2023-12-31-0.65USD/shares365
2023-07-01 to 2023-09-30-0.21USD/shares92
2023-01-01 to 2023-09-30-0.52USD/shares273
2023-04-01 to 2023-06-30-0.15USD/shares91
2023-01-01 to 2023-06-30-0.32USD/shares181
2023-01-01 to 2023-03-31-0.17USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-0.38USD/shares366
2024-07-01 to 2024-09-30-0.05USD/shares92
2024-01-01 to 2024-09-30-0.24USD/shares274
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-06-30-0.19USD/shares182
2024-01-01 to 2024-03-31-0.11USD/shares91
2023-01-01 to 2023-12-31-0.65USD/shares365
2023-07-01 to 2023-09-30-0.21USD/shares92
2023-01-01 to 2023-09-30-0.52USD/shares273
2023-04-01 to 2023-06-30-0.15USD/shares91
2023-01-01 to 2023-06-30-0.32USD/shares181
2023-01-01 to 2023-03-31-0.17USD/shares90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-1,690,825USD366
2023-01-01 to 2023-12-31-813,739USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-12-319,002,383USD
At 2023-12-3110,056,354USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-12-313,759,534USD366
2023-01-01 to 2023-12-314,155,342USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-16,785,939USD366
2023-01-01 to 2023-12-31-31,948,620USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-12-3121,603,242USD
At 2024-09-3016,597,368USD
At 2024-06-3021,955,300USD
At 2024-03-3119,992,800USD
At 2023-12-3125,398,511USD
At 2023-09-3019,260,643USD
At 2023-06-3023,643,953USD
At 2023-03-3128,164,991USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-12-319,824,243USD
At 2024-09-308,284,409USD
At 2024-06-309,644,248USD
At 2024-03-3112,723,644USD
At 2023-12-3114,035,592USD
At 2023-09-3011,672,431USD
At 2023-06-309,985,254USD
At 2023-03-319,453,424USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-12-313,339,885USD
At 2023-12-313,802,170USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-12-313,748,036USD
At 2023-12-313,906,552USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-12-317,319,597USD
At 2023-12-316,057,072USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-12-3141,911,930USD366
2023-01-01 to 2023-12-3153,901,857USD365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-12-312,732,907USD
At 2024-09-303,247,756USD
At 2024-06-304,316,752USD
At 2024-03-313,738,767USD
At 2023-12-313,375,817USD
At 2023-09-302,977,146USD
At 2023-06-302,045,985USD
At 2023-03-311,725,673USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-01-01 to 2024-12-3125,125,991USD366
2023-01-01 to 2023-12-3121,953,237USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-01-01 to 2024-12-3134,995,749USD366
2023-01-01 to 2023-12-3138,307,415USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-12-3154,830,146shares
At 2023-12-3154,240,265shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-12-319,763,884USD
At 2023-12-3115,615,095USD
At 2022-12-3123,832,026USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-12-31310,808,711USD
At 2024-09-30309,687,001USD
At 2024-06-30308,873,978USD
At 2024-03-31307,199,964USD
At 2023-12-31306,187,314USD
At 2023-09-30292,918,387USD
At 2023-06-30291,054,006USD
At 2023-03-31289,537,826USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-12-314,252,013USD
At 2023-12-31529,321USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-12-3111,511,236USD
At 2023-12-3112,058,896USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-12-3112,896,659USD
At 2023-12-3113,270,295USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-12-3113,227,381USD
At 2023-12-3113,092,384USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-12-314,224,998USD
At 2023-12-313,036,030USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-313,770,681USD
At 2023-12-313,958,603USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-12-313,270,812USD
At 2023-12-311,834,485USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2024-12-31419,331USD
At 2023-12-311,380,821USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2024-12-313,585,386USD
At 2023-12-313,705,671USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-22,409,782USD366
2023-01-01 to 2023-12-31-30,060,499USD365

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-16,691,953USD366
2023-01-01 to 2023-12-31-31,046,634USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-20,718,957USD366
2023-01-01 to 2023-12-31-29,246,760USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-01-01 to 2024-12-311,341,262USD366
2023-01-01 to 2023-12-311,239,600USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-5,623,843USD366
2023-01-01 to 2023-12-311,888,121USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-12-311,290,396USD366
2023-01-01 to 2023-12-31376,668USD365

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-01-01 to 2024-12-311,683,461USD366
2023-01-01 to 2023-12-312,403,025USD365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-12-311,720,419USD366
2023-01-01 to 2023-12-31245,616USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-12-31-500,466USD366
2023-01-01 to 2023-12-31-183,273USD365
2023-01-01 to 2023-09-30-471,822USD273
2023-01-01 to 2023-06-30-1,449,881USD181
2023-01-01 to 2023-03-31-1,747,144USD90

Inspect the source

Entity
CYTOSORBENTS CORPORATION / CIK 0001175151
Captured
2026-09-20T07:44:44.168Z
SEC response SHA-256
8bb195ec858f16302b2a8454a5ffe3eff6c1e6cd0312136a64a7a2f621b86836

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175151.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))